Primaquine plus artemisinin combination therapy for reduction of malaria transmission

Promise and risk

Research output: Contribution to journalComment/debate

3 Citations (Scopus)

Abstract

Reduction of gametocyte transmission from humans to mosquitoes is a key component of malaria elimination. The study by Gonçalves and colleagues provides valuable new data on how the addition of low-dose primaquine to artemether-lumefantrine affects reduction of gametocytemia and transmission of gametocytes to mosquitoes in asymptomatically Plasmodium falciparum-infected children without G6PD deficiency, and on the degree to which low-dose primaquine affects hemoglobin levels in these children. The study sets the stage for future research required for consideration of an artemisinin combination therapy (ACT)-primaquine regimen in mass drug administration campaigns. Future studies will need to evaluate toxicity in adults and G6PD deficient persons, assess gametocyte transmission from adults, evaluate different ACT drugs with primaquine, and assess the implications of "rare" toxicities in large treatment populations, such as hemolysis requiring blood transfusion. The study highlights both the promise and the potential risk of ACT-primaquine treatment in malaria elimination campaigns. Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0581-y.

Original languageEnglish (US)
Article number65
JournalBMC Medicine
Volume14
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Primaquine
Malaria
Culicidae
Glucosephosphate Dehydrogenase Deficiency
Therapeutics
Plasmodium falciparum
Hemolysis
Combination Drug Therapy
Blood Transfusion
Hemoglobins
artemisinine
Pharmaceutical Preparations
Population

Keywords

  • Artemether-lumefantrine
  • Artemisinin combination therapy
  • Falciparum
  • Gametocyte
  • Hemolysis
  • Malaria
  • Mass drug administration
  • Membrane feeding assay
  • Primaquine
  • Transmission

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Primaquine plus artemisinin combination therapy for reduction of malaria transmission : Promise and risk. / John, Chandy.

In: BMC Medicine, Vol. 14, No. 1, 65, 2016.

Research output: Contribution to journalComment/debate

@article{98117e02b1bd4c69911e93f3891db385,
title = "Primaquine plus artemisinin combination therapy for reduction of malaria transmission: Promise and risk",
abstract = "Reduction of gametocyte transmission from humans to mosquitoes is a key component of malaria elimination. The study by Gon{\cc}alves and colleagues provides valuable new data on how the addition of low-dose primaquine to artemether-lumefantrine affects reduction of gametocytemia and transmission of gametocytes to mosquitoes in asymptomatically Plasmodium falciparum-infected children without G6PD deficiency, and on the degree to which low-dose primaquine affects hemoglobin levels in these children. The study sets the stage for future research required for consideration of an artemisinin combination therapy (ACT)-primaquine regimen in mass drug administration campaigns. Future studies will need to evaluate toxicity in adults and G6PD deficient persons, assess gametocyte transmission from adults, evaluate different ACT drugs with primaquine, and assess the implications of {"}rare{"} toxicities in large treatment populations, such as hemolysis requiring blood transfusion. The study highlights both the promise and the potential risk of ACT-primaquine treatment in malaria elimination campaigns. Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0581-y.",
keywords = "Artemether-lumefantrine, Artemisinin combination therapy, Falciparum, Gametocyte, Hemolysis, Malaria, Mass drug administration, Membrane feeding assay, Primaquine, Transmission",
author = "Chandy John",
year = "2016",
doi = "10.1186/s12916-016-0611-9",
language = "English (US)",
volume = "14",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Primaquine plus artemisinin combination therapy for reduction of malaria transmission

T2 - Promise and risk

AU - John, Chandy

PY - 2016

Y1 - 2016

N2 - Reduction of gametocyte transmission from humans to mosquitoes is a key component of malaria elimination. The study by Gonçalves and colleagues provides valuable new data on how the addition of low-dose primaquine to artemether-lumefantrine affects reduction of gametocytemia and transmission of gametocytes to mosquitoes in asymptomatically Plasmodium falciparum-infected children without G6PD deficiency, and on the degree to which low-dose primaquine affects hemoglobin levels in these children. The study sets the stage for future research required for consideration of an artemisinin combination therapy (ACT)-primaquine regimen in mass drug administration campaigns. Future studies will need to evaluate toxicity in adults and G6PD deficient persons, assess gametocyte transmission from adults, evaluate different ACT drugs with primaquine, and assess the implications of "rare" toxicities in large treatment populations, such as hemolysis requiring blood transfusion. The study highlights both the promise and the potential risk of ACT-primaquine treatment in malaria elimination campaigns. Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0581-y.

AB - Reduction of gametocyte transmission from humans to mosquitoes is a key component of malaria elimination. The study by Gonçalves and colleagues provides valuable new data on how the addition of low-dose primaquine to artemether-lumefantrine affects reduction of gametocytemia and transmission of gametocytes to mosquitoes in asymptomatically Plasmodium falciparum-infected children without G6PD deficiency, and on the degree to which low-dose primaquine affects hemoglobin levels in these children. The study sets the stage for future research required for consideration of an artemisinin combination therapy (ACT)-primaquine regimen in mass drug administration campaigns. Future studies will need to evaluate toxicity in adults and G6PD deficient persons, assess gametocyte transmission from adults, evaluate different ACT drugs with primaquine, and assess the implications of "rare" toxicities in large treatment populations, such as hemolysis requiring blood transfusion. The study highlights both the promise and the potential risk of ACT-primaquine treatment in malaria elimination campaigns. Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0581-y.

KW - Artemether-lumefantrine

KW - Artemisinin combination therapy

KW - Falciparum

KW - Gametocyte

KW - Hemolysis

KW - Malaria

KW - Mass drug administration

KW - Membrane feeding assay

KW - Primaquine

KW - Transmission

UR - http://www.scopus.com/inward/record.url?scp=85007470579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007470579&partnerID=8YFLogxK

U2 - 10.1186/s12916-016-0611-9

DO - 10.1186/s12916-016-0611-9

M3 - Comment/debate

VL - 14

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 65

ER -